Cargando…
Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
AIMS: The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endothelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasminogen activator inhibitor-1 (PAI-1). We hypothesized that such pat...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663725/ https://www.ncbi.nlm.nih.gov/pubmed/19164335 http://dx.doi.org/10.1093/eurheartj/ehn569 |
_version_ | 1782165919268601856 |
---|---|
author | Mouquet, Frédéric Cuilleret, François Susen, Sophie Sautière, Karine Marboeuf, Philippe Ennezat, Pierre Vladimir McFadden, Eugène Pigny, Pascal Richard, Florence Hennache, Bernadette Vantyghem, Marie Christine Bertrand, Michel Dallongeville, Jean Jude, Brigitte Van Belle, Eric |
author_facet | Mouquet, Frédéric Cuilleret, François Susen, Sophie Sautière, Karine Marboeuf, Philippe Ennezat, Pierre Vladimir McFadden, Eugène Pigny, Pascal Richard, Florence Hennache, Bernadette Vantyghem, Marie Christine Bertrand, Michel Dallongeville, Jean Jude, Brigitte Van Belle, Eric |
author_sort | Mouquet, Frédéric |
collection | PubMed |
description | AIMS: The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endothelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasminogen activator inhibitor-1 (PAI-1). We hypothesized that such patients, in the event of a coronary occlusion, might exhibit a less developed collateral circulation. METHODS AND RESULTS: Three hundred and eighty-seven consecutive patients with at least one coronary occlusion of a major coronary vessel at diagnostic angiography were prospectively enrolled. Collateral development was graded with validated angiographic methods. The MS was defined according to the ATP-III definition. Fasting glucose, adiponectin, insulin concentrations, and PAI-1 were measured at the time of angiography. MS was associated with less developed collateral vessels (P = 0.005). In multivariable analysis adjusting for potential confounding factors including the duration of coronary occlusion (P = 0.0001), fasting glycaemia (P = 0.0007), low adiponectin concentration (P = 0.01), insulin-resistance (HOMA-IR; P = 0.01), high circulating PAI-1 concentration (P = 0.01), and hypertension (P = 0.008) were independently associated with poor coronary collateral vessel development. CONCLUSION: This study shows that in patients with coronary occlusion, collateral circulation is impaired in patients with the MS. This association is partly related to fasting glycaemia and to key parameters linked to insulin resistance. |
format | Text |
id | pubmed-2663725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26637252009-04-02 Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 Mouquet, Frédéric Cuilleret, François Susen, Sophie Sautière, Karine Marboeuf, Philippe Ennezat, Pierre Vladimir McFadden, Eugène Pigny, Pascal Richard, Florence Hennache, Bernadette Vantyghem, Marie Christine Bertrand, Michel Dallongeville, Jean Jude, Brigitte Van Belle, Eric Eur Heart J Clinical Research AIMS: The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endothelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasminogen activator inhibitor-1 (PAI-1). We hypothesized that such patients, in the event of a coronary occlusion, might exhibit a less developed collateral circulation. METHODS AND RESULTS: Three hundred and eighty-seven consecutive patients with at least one coronary occlusion of a major coronary vessel at diagnostic angiography were prospectively enrolled. Collateral development was graded with validated angiographic methods. The MS was defined according to the ATP-III definition. Fasting glucose, adiponectin, insulin concentrations, and PAI-1 were measured at the time of angiography. MS was associated with less developed collateral vessels (P = 0.005). In multivariable analysis adjusting for potential confounding factors including the duration of coronary occlusion (P = 0.0001), fasting glycaemia (P = 0.0007), low adiponectin concentration (P = 0.01), insulin-resistance (HOMA-IR; P = 0.01), high circulating PAI-1 concentration (P = 0.01), and hypertension (P = 0.008) were independently associated with poor coronary collateral vessel development. CONCLUSION: This study shows that in patients with coronary occlusion, collateral circulation is impaired in patients with the MS. This association is partly related to fasting glycaemia and to key parameters linked to insulin resistance. Oxford University Press 2009-04 2009-01-22 /pmc/articles/PMC2663725/ /pubmed/19164335 http://dx.doi.org/10.1093/eurheartj/ehn569 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org |
spellingShingle | Clinical Research Mouquet, Frédéric Cuilleret, François Susen, Sophie Sautière, Karine Marboeuf, Philippe Ennezat, Pierre Vladimir McFadden, Eugène Pigny, Pascal Richard, Florence Hennache, Bernadette Vantyghem, Marie Christine Bertrand, Michel Dallongeville, Jean Jude, Brigitte Van Belle, Eric Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 |
title | Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 |
title_full | Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 |
title_fullStr | Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 |
title_full_unstemmed | Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 |
title_short | Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 |
title_sort | metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663725/ https://www.ncbi.nlm.nih.gov/pubmed/19164335 http://dx.doi.org/10.1093/eurheartj/ehn569 |
work_keys_str_mv | AT mouquetfrederic metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT cuilleretfrancois metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT susensophie metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT sautierekarine metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT marboeufphilippe metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT ennezatpierrevladimir metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT mcfaddeneugene metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT pignypascal metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT richardflorence metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT hennachebernadette metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT vantyghemmariechristine metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT bertrandmichel metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT dallongevillejean metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT judebrigitte metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 AT vanbelleeric metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1 |